<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney stones in children: Epidemiology and risk factors</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney stones in children: Epidemiology and risk factors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney stones in children: Epidemiology and risk factors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jodi Smith, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">F Bruder Stapleton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laurence S Baskin, MD, FAAP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 01, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Kidney stones are increasingly recognized in children. The epidemiology and etiology of kidney stones in children will be reviewed here. The clinical manifestations, diagnosis, acute management, and prevention of recurrence are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6123.html" rel="external">"Kidney stones in children: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6114.html" rel="external">"Kidney stones in children: Acute management"</a> and  <a class="medical medical_review" href="/z/d/html/6109.html" rel="external">"Kidney stones in children: Prevention of recurrent stones"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H3698708679"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>The diagnosis of pediatric kidney stones has increased as illustrated by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A study using data from a commercial health claims database reported the annual rate of pediatric cases for urinary stone disease in the United States rose from 2005 to a peak of 65.2 cases per 100,000 person years in 2011 [<a href="#rid1">1</a>]. Similarly, in a study of a database that included all emergency visits, surgical procedures, and hospital admissions in the state of South Carolina, the incidence of such encounters for nephrolithiasis among individuals aged 15 to 19 years old increased by 25 percent every 5 years between 1997 and 2012 [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An Israeli study based on reported histories during compulsory medical evaluations of 17-year-old military enlistees found the average prevalence rate increased from 69 to 120 cases per 100,000 individuals between the two time periods of 1980 to 1995 and 2010 to 2012 [<a href="#rid3">3</a>]. During the same time period, the authors also noted an increase in body mass index and hypothesized whether a possible association existed.</p><p></p><p>Data from the United States Pediatric Health Information System (PHIS) have shown a proportional increase in hospitalizations due to pediatric kidney stones with a diagnosis of kidney stones made in 1 case for every 685 pediatric hospitalizations [<a href="#rid4">4,5</a>].</p><p class="headingAnchor" id="H3667801674"><span class="h2">Demographic features</span><span class="headingEndMark"> — </span>Demographic factors that may affect the incidence of kidney stones include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age</strong> – The incidence of kidney stones is lower in children than in adults, and the incidence increases with age, with adolescents having the highest risk of kidney stones [<a href="#rid1">1,6-8</a>]. In a population-based United States study of patients over 10 years of age, adolescents between 10 and 19 years of age accounted for only 4 percent of the total episodes of kidney stones [<a href="#rid9">9</a>]. For the total population, the incidence of kidney stones was 109 per 100,000 men per year and 36 per 100,000 women per year. The explanation for the lower pediatric incidence is unknown, but may be due in part to the higher concentrations of crystal formation inhibitors such as citrate and magnesium in the urine of children compared with adults [<a href="#rid10">10,11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sex</strong> – Children do not have the strong male predominance seen in adults with kidney stones. Some studies do show a slightly higher incidence in boys [<a href="#rid5">5,12-17</a>], whereas other studies, including some from Taiwan and the United States, have reported a higher incidence in girls compared with boys [<a href="#rid1">1,2,18</a>].</p><p></p><p class="bulletIndent1">In the United States, sex distribution varied with age in children who were hospitalized for kidney stones [<a href="#rid19">19</a>]. Boys were more commonly affected in the first decade of life and girls in the second decade. This sex variation may reflect that boys are more likely to have obstructive urinary malformations resulting in kidney stones that typically present early, whereas there is an increase in the rate of urinary tract infections, another risk factor for kidney stones, in postpubertal sexually active girls [<a href="#rid20">20</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Geography</strong> – Similar to adults, the incidence of kidney stones in children varies worldwide, with the highest incidence occurring in endemic areas, such as in Turkey and Thailand. Data from the National Health Insurance Research Database reported that the risk of kidney stones was greater in children who lived in urban areas and in those with urinary tract infection [<a href="#rid18">18</a>].</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Overview of risk factors</span><span class="headingEndMark"> — </span>In children with kidney stones, an underlying risk factor is identified in as high as 75 to 85 percent of affected children [<a href="#rid12">12-17</a>]. In most children, kidney stones are associated with a urinary metabolic abnormality, urinary tract infection, and/or a structural kidney or urinary tract abnormality [<a href="#rid12">12-17,21,22</a>].</p><p class="headingAnchor" id="H4"><span class="h1">METABOLIC RISK FACTORS</span></p><p class="headingAnchor" id="H1694416115"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>The two mechanisms by which metabolic factors enhance stone formation include:</p><p class="bulletIndent1"><span class="glyph">●</span>Excessive solute concentration – High urinary concentrations of calcium, oxalate, uric acid, and cystine due to increased renal excretion and/or low urine volume cause solute excess. This leads to solute supersaturation and precipitation, and results in the formation of crystals, which may aggregate into stones.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased levels of inhibitors of stone formation – Natural inhibitors of urinary stone formation include citrate, magnesium, and pyrophosphate. Low levels of these inhibitors, particularly hypocitraturia, are associated with kidney stones in both adults and children.</p><p></p><p>In two case series of children with kidney stones, approximately 90 percent of patients had at least one metabolic risk factor [<a href="#rid23">23,24</a>]. Common risk factors include low urine flow rate, hypercalciuria and hypocitraturia. </p><p class="headingAnchor" id="H2898230481"><span class="h2">Stone composition</span><span class="headingEndMark"> — </span>In general, stone composition varies based on age and sex in both adults and children  (<a class="graphic graphic_figure graphicRef129537" href="/z/d/graphic/129537.html" rel="external">figure 1</a>). Based upon case series, the frequency of different stone composition in children is as follows [<a href="#rid21">21,25,26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Calcium oxalate – 45 to 65 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Calcium phosphate – 6 to 30 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Struvite – 4 to 13 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Cystine – 2 to 5 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Uric acid – 0 to 4 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Mixed or miscellaneous – 4 to 32 percent</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Hypercalciuria</span></p><p class="headingAnchor" id="H1296650134"><span class="h3">Overview</span><span class="headingEndMark"> — </span>Hypercalciuria is the most common metabolic abnormality associated with pediatric stone disease [<a href="#rid27">27,28</a>]. It is identified as the major contributing factor in at least half of the children with a metabolic cause for kidney stones [<a href="#rid12">12,21</a>].</p><p>Hypercalciuria may also cause nephrocalcinosis, a condition in which calcium salts precipitate out of solution within the kidney parenchyma. Hematuria, dysuria, and urinary frequency can be seen in children with hypercalciuria [<a href="#rid29">29-31</a>]. (See  <a class="medical medical_review" href="/z/d/html/6108.html" rel="external">"Evaluation of gross hematuria in children"</a> and  <a class="medical medical_review" href="/z/d/html/6089.html" rel="external">"Evaluation of microscopic hematuria in children"</a>.)</p><p>Children with hypercalciuria and isolated microscopic hematuria are at risk for kidney stones. An observational study of children with hematuria found 58 children with hypercalciuria. Of those with hematuria and hypercalciuria, 17 percent (10/58) had developed a kidney stone within a mean interval of 13 months [<a href="#rid31">31</a>]. In another observational study of children with unexplained isolated hematuria, 13 percent (8/60) of patients with hypercalciuria had developed kidney stones within a one to four year follow-up period [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H924842548"><span class="h3">Definition</span><span class="headingEndMark"> — </span>Hypercalciuria is defined as urinary calcium excretion rate that is greater than 4 mg/kg per 24 hours in a child greater than two years of age who is ingesting a routine diet  (<a class="graphic graphic_table graphicRef70589" href="/z/d/graphic/70589.html" rel="external">table 1</a>) [<a href="#rid32">32,33</a>]. The diagnosis of hypercalciuria is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6109.html" rel="external">"Kidney stones in children: Prevention of recurrent stones", section on 'Definitions of specific urine metabolic abnormalities'</a>.)</p><p class="headingAnchor" id="H1634517998"><span class="h3">Pathogenesis</span><span class="headingEndMark"> — </span>Three mechanisms contribute to higher urinary calcium excretion [<a href="#rid34">34-38</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased intestinal absorption ("absorptive hypercalciuria") in which there is an increase in intestinal calcium absorption resulting in excess serum calcium and high urinary calcium excretion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased renal losses ("renal hypercalciuria") in which there is a defect in renal tubular calcium reabsorption resulting in an increase in urinary calcium excretion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased bone resorption ("resorptive hypercalciuria") in which the source of the excess calcium is bone.</p><p></p><p>Both genetic and environmental factors can affect these mechanisms, thereby increasing urinary calcium excretion and the risk for kidney stones. As an example, high dietary sodium intake increases urinary calcium excretion. (See  <a class="medical medical_review" href="/z/d/html/7375.html" rel="external">"Kidney stones in adults: Epidemiology and risk factors", section on 'Sodium'</a>.)</p><p class="headingAnchor" id="H6"><span class="h4">Genetic factors</span><span class="headingEndMark"> — </span>There is evidence that many cases (and likely a majority of cases) of idiopathic hypercalciuria represent a complex interaction among many genes and environmental factors [<a href="#rid39">39,40</a>]. Proposed specific involvement includes genes that affect the calcium sensing receptor, calcium channels in the intestine and kidney, vitamin D receptor, enzymes related to vitamin D metabolism (eg, CYP24A1 deficiency), intestinal oxalate exchangers, renal and bone resorption, and renal excretion of calcium, oxalate, and citrate. (See  <a class="medical medical_review" href="/z/d/html/7375.html" rel="external">"Kidney stones in adults: Epidemiology and risk factors", section on 'Family history'</a>.)</p><p>Less commonly, a monogenic defect can cause hypercalciuria via any of the three physiologic mechanisms that results in kidney stones or nephrocalcinosis [<a href="#rid38">38-40</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Monogenic disorders that increase intestinal absorption of calcium include hypophosphatemia and absorptive hypercalciuria, enzymes related to vitamin D metabolism, congenital malabsorption disorders (ie, congenital lactase deficiency, congenital sucrase-isomaltase deficiency, and glucose/galactose malabsorption), and Blue diaper syndrome. (See  <a class="medical medical_review" href="/z/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia"</a> and  <a class="medical medical_review" href="/z/d/html/839.html" rel="external">"Etiology of hypercalcemia", section on 'Congenital lactase deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monogenic disorders that impair renal tubular calcium reabsorption include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dent disease, also referred to as X-linked recessive kidney stones (see  <a class="medical medical_review" href="/z/d/html/7363.html" rel="external">"Dent disease (X-linked recessive nephrolithiasis)"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bartter syndrome (see  <a class="medical medical_review" href="/z/d/html/2344.html" rel="external">"Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Wilson disease (see  <a class="medical medical_review" href="/z/d/html/83837.html" rel="external">"Wilson disease: Clinical manifestations, diagnosis, and natural history", section on 'Other organs'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Glycogen storage disease type 1a (see  <a class="medical medical_review" href="/z/d/html/2946.html" rel="external">"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)", section on 'Clinical features'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hereditary distal renal tubular acidosis (RTA) with identified mutations in either the basolateral chloride-bicarbonate cotransporter or in the apical hydrogen-ATPase (see  <a class="medical medical_review" href="/z/d/html/2328.html" rel="external">"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis", section on 'Distal (type 1) RTA'</a> and  <a class="medical medical_review" href="/z/d/html/2369.html" rel="external">"Nephrolithiasis in renal tubular acidosis"</a> and  <a class="medical medical_review" href="/z/d/html/2327.html" rel="external">"Overview and pathophysiology of renal tubular acidosis and the effect on potassium balance"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (see  <a class="medical medical_review" href="/z/d/html/829.html" rel="external">"Hypomagnesemia: Causes of hypomagnesemia", section on 'Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC)'</a> and  <a class="medical medical_review" href="/z/d/html/829.html" rel="external">"Hypomagnesemia: Causes of hypomagnesemia"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monogenic disorders that increase bone absorption include multiple endocrine neoplasia type 1 syndrome with hyperparathyroidism [<a href="#rid41">41</a>], and McCune-Albright syndrome. (See  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h4">Environmental factors</span><span class="headingEndMark"> — </span>The following environmental factors can increase urinary calcium excretion [<a href="#rid22">22,34-37</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Immobilization with increased bone resorption [<a href="#rid17">17,42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medications such as loop diuretics, which increase calcium renal excretion (especially in neonates), and glucocorticoids, which increase bone resorption. (See  <a class="medical medical_review" href="/z/d/html/6125.html" rel="external">"Nephrocalcinosis in neonates"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Excessive amounts of vitamin D.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High sodium intake (ie, a high salt diet). (See  <a class="medical medical_review" href="/z/d/html/7375.html" rel="external">"Kidney stones in adults: Epidemiology and risk factors", section on 'Sodium'</a>.) </p><p></p><p>The role of calcium, routine dietary vitamin D supplementation, and other solutes as risk factors in kidney stone formation is unclear and is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7375.html" rel="external">"Kidney stones in adults: Epidemiology and risk factors", section on 'Dietary factors'</a>.)</p><p class="headingAnchor" id="H8"><span class="h4">Other factors</span><span class="headingEndMark"> — </span>Secondary forms of hypercalciuria include hyperparathyroidism [<a href="#rid41">41</a>], chronic metabolic acidosis in association with hypocitraturia, hypercalcemia from any cause, and hypophosphatemia. (See  <a class="medical medical_review" href="/z/d/html/2031.html" rel="external">"Primary hyperparathyroidism: Clinical manifestations"</a> and <a class="local">'Hypocitraturia'</a> below and  <a class="medical medical_review" href="/z/d/html/839.html" rel="external">"Etiology of hypercalcemia"</a> and  <a class="medical medical_review" href="/z/d/html/830.html" rel="external">"Hypophosphatemia: Causes of hypophosphatemia"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Hyperoxaluria</span><span class="headingEndMark"> — </span>In case series of pediatric kidney stone disease, hyperoxaluria was detected in 10 to 20 percent of children [<a href="#rid12">12,21</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Hyperoxaluria is defined as a urinary oxalate excretion rate that is greater than 0.7 mmol (62 mg)/1.73 m<sup>2</sup> per 24 hours or random urine oxalate to creatinine ratio greater than normal for age  (<a class="graphic graphic_table graphicRef70589" href="/z/d/graphic/70589.html" rel="external">table 1</a>) [<a href="#rid32">32</a>]. The diagnosis of hyperoxaluria is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6109.html" rel="external">"Kidney stones in children: Prevention of recurrent stones", section on 'Definitions of specific urine metabolic abnormalities'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – Any patient with elevated urinary oxalate requires evaluation for hyperoxaluria. Causes of hyperoxaluria include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary hyperoxaluria – The three types of primary hyperoxaluria (types I, II, and III) are rare autosomal disorders affecting genes that encode enzymes involved in glyoxylate metabolism. These disorders are characterized by enhanced conversion of glyoxalate to poorly soluble oxalate, resulting in increased serum oxalate and hyperoxaluria, which can lead to kidney stones, nephrocalcinosis, chronic kidney disease, and end stage kidney disease. These disorders are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6141.html" rel="external">"Primary hyperoxaluria"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fat malabsorption (ie, enteric hyperoxaluria) – Children with fat malabsorption may have an enhanced enteric absorption of oxalate known as enteric hyperoxaluria. Excess fatty acid binds calcium, leaving less available calcium to combine with oxalate, and thus more free oxalate is absorbed. Children with inflammatory bowel disease [<a href="#rid43">43</a>], extensive bowel resection, pancreatitis, and cystic fibrosis are at risk for hyperoxaluria and kidney stones. (See  <a class="medical medical_review" href="/z/d/html/7375.html" rel="external">"Kidney stones in adults: Epidemiology and risk factors", section on 'High urine oxalate'</a> and  <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults", section on 'Malabsorption'</a> and  <a class="medical medical_review" href="/z/d/html/5886.html" rel="external">"Chronic complications of short bowel syndrome in children", section on 'Hyperoxaluria and kidney stones'</a>.)</p><p></p><p class="bulletIndent2">In these patients, the degree of hyperoxaluria is dependent on the dietary intake of oxalate. Urinary oxalate excretion can be reduced by decreasing dietary oxalate, eating a low-fat diet, and increasing fluid intake. In addition, taking dietary calcium supplements when eating high oxalate foods facilitates calcium binding to the oxalate in the diet.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Idiopathic hyperoxaluria often occurs in conjunction with hypercalciuria resulting in calcium oxalate crystals and stones  (<a class="graphic graphic_picture graphicRef65169 graphicRef67694" href="/z/d/graphic/65169.html" rel="external">picture 1A-B</a>). The underlying pathogenesis of idiopathic hyperoxaluria is unknown. It has been proposed that affected patients have increased urinary oxalate excretion because of increased oxalate production or enhanced gastrointestinal oxalate absorption.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Excessive oxalate ingestion – Ethylene glycol, ascorbic acid, and <a class="drug drug_general" data-topicid="118670" href="/z/d/drug information/118670.html" rel="external">methoxyflurane</a> are metabolized to form oxalate. Excessive ingestions of these products result in increased serum oxalate and hyperoxaluria. (See  <a class="medical medical_review" href="/z/d/html/336.html" rel="external">"Methanol and ethylene glycol poisoning: Pharmacology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Hyperuricosuria</span><span class="headingEndMark"> — </span>While uric acid stones are rare in children, hyperuricosuria is detected in 2 to 8 percent of children with kidney stones. Determining whether uric acid excretion is abnormally elevated in children can be challenging. Uric acid excretion is highest in infants and remains high in children until adolescence when values decrease to adult values. In infants, the normal urinary uric acid excretion is so high that crystals may precipitate in the diaper and be misidentified as blood  (<a class="graphic graphic_picture graphicRef61827 graphicRef73642" href="/z/d/graphic/61827.html" rel="external">picture 2A-B</a> and <a class="graphic graphic_picture graphicRef65328" href="/z/d/graphic/65328.html" rel="external">picture 3</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Definition – The definition of hyperuricosuria is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6109.html" rel="external">"Kidney stones in children: Prevention of recurrent stones", section on 'Definitions of specific urine metabolic abnormalities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Etiology – Increased urinary excretion of uric acid can result from either enhanced renal excretion or increased production of uric acid.</p><p></p><p class="bulletIndent1">Idiopathic hyperuricosuria is thought to be due to a defect in renal tubular uric acid excretion and is often seen in conjunction with hypercalciuria. It is also frequently present in families and is generally asymptomatic. However, in some families, formation of uric acid stones occurs, usually in individuals with constantly acidic urine.</p><p></p><p class="bulletIndent1">In childhood, pure urate stones are uncommon and are generally due to overproduction of uric acid. Causes include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tumor lysis syndrome (see  <a class="medical medical_review" href="/z/d/html/1154.html" rel="external">"Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Lymphoproliferative and myeloproliferative disorders (see  <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Rare genetic disorders, including:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Lesch-Nyhan (hypoxanthine-guanine phosphoribosyl transferase deficiency) (see  <a class="medical medical_review" href="/z/d/html/6232.html" rel="external">"Hyperkinetic movement disorders in children", section on 'Lesch-Nyhan syndrome'</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Uric acid transporter mutations (see  <a class="medical medical_review" href="/z/d/html/7378.html" rel="external">"Kidney stones in adults: Uric acid nephrolithiasis"</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Autosomal dominant tubulointerstitial kidney disease (see  <a class="medical medical_review" href="/z/d/html/1685.html" rel="external">"Autosomal dominant tubulointerstitial kidney disease"</a>)</p><p class="bulletIndent3"><span class="glyph">-</span><em>G</em>lycogen storage diseases (see  <a class="medical medical_review" href="/z/d/html/2946.html" rel="external">"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)"</a> and  <a class="medical medical_review" href="/z/d/html/2907.html" rel="external">"Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)"</a>)</p><p></p><p class="bulletIndent1">In addition, a high dietary intake of purines or hemolysis has been associated with uric acid kidney stones. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical significance – Many of the conditions with hyperuricosuria can also lead to acute kidney failure due to precipitation of uric acid within the renal tubules. (See  <a class="medical medical_review" href="/z/d/html/7379.html" rel="external">"Uric acid kidney diseases", section on 'Acute uric acid nephropathy'</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Cystinuria</span><span class="headingEndMark"> — </span>Cystine stones account for 5 percent of pediatric kidney stone disease and are caused by cystinuria, an autosomal recessive disorder of renal tubular transport. Cystinuria is characterized by excessive urinary excretion of the dibasic amino acids cystine, ornithine, lysine, and arginine. Cystinuria appears to be caused by mutations and/or genomic rearrangements in two genes, SLC3A1 and SLC7A9. Recurrent kidney stones appear to be the only manifestation of cystinuria; 20 to 25 percent of individuals with cystinuria have pathognomonic colorless, flat, hexagonal cystine crystals in the urinary sediment  (<a class="graphic graphic_picture graphicRef56834" href="/z/d/graphic/56834.html" rel="external">picture 4</a>). (See  <a class="medical medical_review" href="/z/d/html/7362.html" rel="external">"Cystinuria and cystine stones"</a>.)</p><p>Evaluation and diagnosis of cystinuria in children with kidney stones are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6109.html" rel="external">"Kidney stones in children: Prevention of recurrent stones", section on 'Definitions of specific urine metabolic abnormalities'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Hypocitraturia</span><span class="headingEndMark"> — </span>Citrate is an inhibitor of calcium oxalate and calcium phosphate crystallization. In adult patients with idiopathic kidney stones, hypocitraturia is a frequent finding. Hypocitraturia has also been reported in up to 68 percent of children with kidney stones [<a href="#rid23">23,44,45</a>]. In one study, citrate excretion was lower in 78 children with calcium stones compared with a control group of 24 healthy non stone-forming children [<a href="#rid46">46</a>].</p><p>Citrate excretion is greater in children than adults. In children, hypocitraturia is defined as a urinary citrate excretion rate that is less than 400 mg/g of creatinine in a 24 hour urine collection  (<a class="graphic graphic_table graphicRef70589" href="/z/d/graphic/70589.html" rel="external">table 1</a>) [<a href="#rid47">47</a>]. Diagnosis of hypocitraturia is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6109.html" rel="external">"Kidney stones in children: Prevention of recurrent stones", section on 'Definitions of specific urine metabolic abnormalities'</a>.)</p><p>Citrate combines with calcium in the tubular lumen to form a nondissociable but soluble complex resulting in less free calcium available to combine with oxalate. Citrate also appears to inhibit crystal agglomeration, in which individual calcium oxalate crystals combine to form a stone. Citrate also alkalinizes the urine.</p><p>Children with chronic metabolic acidosis have an increased risk of kidney stones. In these patients, because of enhanced proximal renal tubular citrate reabsorption, citrate excretion is decreased, leading to stone formation. Conditions associated with chronic metabolic acidosis and kidney stones include: </p><p class="bulletIndent1"><span class="glyph">●</span>Conditions causing chronic diarrhea (ie, cystic fibrosis, inflammatory bowel disease, short bowel syndrome)</p><p class="bulletIndent1"><span class="glyph">●</span>Use of carbonic anhydrase inhibitors (eg, <a class="drug drug_pediatric" data-topicid="12851" href="/z/d/drug information/12851.html" rel="external">topiramate</a>, <a class="drug drug_pediatric" data-topicid="12612" href="/z/d/drug information/12612.html" rel="external">zonisamide</a> and diamox)</p><p class="bulletIndent1"><span class="glyph">●</span>Ketogenic diet</p><p class="bulletIndent1"><span class="glyph">●</span>Glycogen storage disease</p><p class="bulletIndent1"><span class="glyph">●</span>RTA, including acquired forms due to medications (ie, <a class="drug drug_pediatric" data-topicid="13373" href="/z/d/drug information/13373.html" rel="external">ifosfamide</a>) or recreational drugs (eg, toluene exposure from glue sniffing) stones [<a href="#rid48">48</a>]</p><p></p><p>Although the cause of idiopathic hypocitraturia is unknown, proposed etiologies include ingestion of a high protein diet and polygenetic factors. (See  <a class="medical medical_review" href="/z/d/html/7375.html" rel="external">"Kidney stones in adults: Epidemiology and risk factors", section on 'Low urine citrate'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Melamine exposure</span><span class="headingEndMark"> — </span>Melamine is a synthetic product used to form resins with formaldehyde and is found in a variety of products in which resin-based coatings are used. The stones are not radiopaque and therefore not seen on plain films; however, they are easily visualized by abdominal ultrasonography or computed tomography.</p><p>Increased melamine exposure has been linked to urolithiasis in both children and adults. This risk was highlighted by the 2008 melamine-tainted baby formula in China that resulted in over 50,000 affected infants, including 13,000 who were hospitalized for acute kidney failure due to urinary obstruction, and six deaths [<a href="#rid49">49-53</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Other metabolic causes</span><span class="headingEndMark"> — </span>There are a wide range of disorders that result in urine solute excretion abnormalities that increase the risk of kidney stones. They include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>High animal protein diet</strong> – Diets with a high content of animal protein can result in high urinary excretion rates of uric acid, calcium, and oxalate, and low urinary excretion rate of citrate. These changes in urinary solute excretion may predispose the child to the formation of calcium oxalate crystals and stones. We generally do not restrict children’s protein intake because protein is required for appropriate growth, but we do obtain a dietary history which includes protein intake and source (ie, animal, plant).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ketogenic diet</strong> – Kidney stones are reported in 3 to 10 percent of children treated with a ketogenic diet for management of their seizures disorders [<a href="#rid54">54-57</a>]. Urinary metabolic abnormalities include hypercalciuria, hyperuricosuria, and hypocitraturia. In patients with kidney stones, the stone composition varies and includes calcium oxalate, uric acid, and ammonium urate, as well as mixed stones of calcium and uric acid. (See  <a class="medical medical_review" href="/z/d/html/14438.html" rel="external">"Ketogenic dietary therapies for the treatment of epilepsy"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cystic fibrosis</strong> – Patients with cystic fibrosis have an increased risk of kidney stones, most commonly due to calcium oxalate, and nephrocalcinosis [<a href="#rid58">58,59</a>]. Although hyperuricosuria, hypercalciuria, and hypocitraturia can be present, hyperoxaluria due to enhanced enteric oxalate absorption is thought to be the primary contributor to stone formation. In addition, tubular dysfunction from cotrimoxazole and <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">ceftazidime</a> therapy may play a role in kidney stones [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs</strong> – Many drugs alter solute excretion such as <a class="drug drug_pediatric" data-topicid="12851" href="/z/d/drug information/12851.html" rel="external">topiramate</a>, <a class="drug drug_pediatric" data-topicid="12612" href="/z/d/drug information/12612.html" rel="external">zonisamide</a>, <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">furosemide</a>, <a class="drug drug_pediatric" data-topicid="13213" href="/z/d/drug information/13213.html" rel="external">acetazolamide</a>, and <a class="drug drug_pediatric" data-topicid="13339" href="/z/d/drug information/13339.html" rel="external">allopurinol</a>, resulting in stone formation. A rare complication of allopurinol therapy is secondary xanthinuria and hypouricosuria. Some classes of oral antibiotics (oral cephalosporins, fluoroquinolones, sulfas, <a class="drug drug_pediatric" data-topicid="12645" href="/z/d/drug information/12645.html" rel="external">nitrofurantoin</a>, and broad-spectrum penicillins) have been associated with increased risk of kidney stones [<a href="#rid60">60</a>]. The greatest risk was observed among younger children, those with the most recent use, and those on high doses or with prolonged use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inborn errors of metabolism</strong> – Inborn errors of metabolism associated with kidney stones include abnormalities in purine and pyrimidine metabolism, such as the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adenine phosphoribosyltransferase deficiency, a rare inborn error of purine metabolism, is an autosomal recessive trait that is associated with radiopaque calculi composed of 2,8-dehydoxyadenine [<a href="#rid61">61,62</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Xanthine oxidase deficiency, an autosomal disorder of purine metabolism, results in xanthine calculi in one-third of affected patients [<a href="#rid63">63</a>]. These patients have a low urinary excretion of uric acid.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Orotic aciduria is a rare inborn error of pyrimidine metabolism that is recessively inherited. This disorder is characterized by an onset in early infancy, growth failure, developmental delay, hypochromic anemia, and excessive urinary excretion of orotic acid, an intermediary of uridine synthesis [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another inborn error of metabolism, alkaptonuria, is a disorder of tyrosine metabolism that is usually associated with kidney stones in adulthood, but there are cases of kidney stones reported in childhood [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/z/d/html/2935.html" rel="external">"Disorders of tyrosine metabolism", section on 'Alkaptonuria'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lesch-Nyhan syndrome (hypoxanthine-guanine phosphoribosyl transferase deficiency) results in a marked increase in production of uric acid and hyperuricemia. (See  <a class="medical medical_review" href="/z/d/html/6232.html" rel="external">"Hyperkinetic movement disorders in children", section on 'Lesch-Nyhan syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">INFECTION</span><span class="headingEndMark"> — </span>Infection may be the primary cause of a stone or occur concomitantly with a underlying urinary metabolic abnormality or structural abnormality.</p><p>Functional or anatomic obstruction of the urinary tract predisposes children to stasis and infection, which promote stone formation. Because boys are more likely to have obstructive uropathy, 80 percent of children with stones associated with infections are male. Infection-associated stones are usually detected before five years of age. All races are equally affected. Improvements in the detection and repair of obstructive uropathy have reduced the incidence of stones due to infections.</p><p>Bacteria that produce the enzyme urease are strongly associated with pediatric kidney stones and include Proteus, Providencia, Klebsiella, Pseudomonas, and enterococci. Urease breaks down urea to form ammonium and bicarbonate, which creates a favorable biochemical milieu for the formation of struvite stones (magnesium ammonium phosphate). Struvite stones, which can contain carbonate apatite, tend to branch, enlarge, and often fill the renal calyces, producing a "staghorn" appearance  (<a class="graphic graphic_diagnosticimage graphicRef62009" href="/z/d/graphic/62009.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef72669" href="/z/d/graphic/72669.html" rel="external">image 2</a>). (See  <a class="medical medical_review" href="/z/d/html/7372.html" rel="external">"Kidney stones in adults: Struvite (infection) stones"</a>.)</p><p>In addition, infections may also produce a soft radiolucent mucoid substance called "matrix concretion" that may calcify readily and account for the rapid formation of some infection-related calculi.</p><p>Xanthogranulomatous pyelonephritis is a rare, severe chronic infection of the kidney that leads to renal parenchymal destruction and chronic inflammation characterized by lipid-laden macrophages [<a href="#rid66">66-68</a>]. In 70 percent of affected children, obstruction is caused by kidney stones, resulting in a nonfunctioning or poorly functioning kidney. Nephrectomy or partial nephrectomy is often required to treat these patients [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/z/d/html/8058.html" rel="external">"Xanthogranulomatous pyelonephritis"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">CONGENITAL/STRUCTURAL ABNORMALITIES</span><span class="headingEndMark"> — </span>In case series of children with kidney stones, structural abnormalities are reported in 10 to 25 percent of patients [<a href="#rid21">21,70,71</a>]. Congenital and structural abnormalities that are accompanied by urinary stasis are associated with kidney stones. Urinary stasis and turbulent urine flow predispose to crystal and stone formation.</p><p>Kidney and urinary tract abnormalities associated with urinary stasis and kidney stones include:</p><p class="bulletIndent1"><span class="glyph">●</span>Ureteropelvic junction (UPJ) obstruction – The association remains even after repair of the UPJ obstruction due to urinary stasis (see  <a class="medical medical_review" href="/z/d/html/6585.html" rel="external">"Congenital ureteropelvic junction obstruction"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autosomal dominant polycystic kidney disease (see  <a class="medical medical_review" href="/z/d/html/1680.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Kidney manifestations", section on 'Nephrolithiasis'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medullary sponge disease (see  <a class="medical medical_review" href="/z/d/html/7369.html" rel="external">"Medullary sponge kidney", section on 'Kidney stones and nephrocalcinosis'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Horseshoe kidney  (<a class="graphic graphic_diagnosticimage graphicRef73581" href="/z/d/graphic/73581.html" rel="external">image 3</a>) (see  <a class="medical medical_review" href="/z/d/html/6107.html" rel="external">"Renal ectopic and fusion anomalies", section on 'Horseshoe kidney'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bladder exstrophy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Augmentation of the bladder – Patients who have surgically augmented bladders are at risk for kidney stones, most commonly bladder stones composed of struvite [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurogenic bladder.</p><p></p><p class="headingAnchor" id="H4147061178"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111700.html" rel="external">"Society guideline links: Pediatric nephrolithiasis"</a>.)</p><p class="headingAnchor" id="H30431309"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/17221.html" rel="external">"Patient education: Kidney stones in children (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis – </strong>Urinary stones develop when there is precipitation of solutes because of urinary solute supersaturation. This is due to two mechanisms (see <a class="local">'Pathogenesis'</a> above).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Excessive solute concentration</strong> due to increased urinary concentration of solutes due to increased renal excretion and/or low urine volume. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Decreased levels of inhibitors</strong> of stone formation, including citrate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – An underlying risk factor is identified in 75 to 85 percent of children with kidney stones. Predisposing conditions include a urinary metabolic abnormality, infection, and/or structural abnormality of the kidney or urinary tract. (See <a class="local">'Overview of risk factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Metabolic risk factors</strong> – A urinary metabolic abnormality is identified in approximately 40 to 50 percent of children with kidney stones. The most common disorder is hypercalciuria, followed by hyperoxaluria, and hypocitraturia. Hyperuricosuria and cystinuria are less commonly seen in children with pediatric kidney stones. (See <a class="local">'Metabolic risk factors'</a> above.)</p><p></p><p class="bulletIndent2">Monogenic disorders that increase intestinal absorption of calcium, impair renal tubular calcium reabsorption, or increase bone absorption can lead to hypercalciuria. (See <a class="local">'Genetic factors'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Urinary tract infection</strong> – In 20 to 25 percent of children with kidney stones, a urinary tract infection (UTI) is detected or there is a history of a UTI. Infection may be the primary cause of pediatric kidney stones or occur concomitantly with underlying urinary metabolic abnormality or structural abnormality. Bacteria that produce the enzyme urease are strongly associated with pediatric kidney stones and include Proteus, Providencia, Klebsiella, Pseudomonas, and enterococci. (See <a class="local">'Infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Structural abnormalities</strong> – Structural abnormalities are reported in 10 to 25 percent of children with kidney stones. In these children, urinary stasis predisposes to crystal formation and stone formation. (See <a class="local">'Congenital/structural abnormalities'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ward JB, Feinstein L, Pierce C, et al. Pediatric Urinary Stone Disease in the United States: The Urologic Diseases in America Project. Urology 2019; 129:180.</a></li><li><a class="nounderline abstract_t">Tasian GE, Ross ME, Song L, et al. Annual Incidence of Nephrolithiasis among Children and Adults in South Carolina from 1997 to 2012. Clin J Am Soc Nephrol 2016; 11:488.</a></li><li><a class="nounderline abstract_t">Alfandary H, Haskin O, Davidovits M, et al. Increasing Prevalence of Nephrolithiasis in Association with Increased Body Mass Index in Children: A Population Based Study. J Urol 2018; 199:1044.</a></li><li><a class="nounderline abstract_t">Routh JC, Graham DA, Nelson CP. Epidemiological trends in pediatric urolithiasis at United States freestanding pediatric hospitals. J Urol 2010; 184:1100.</a></li><li><a class="nounderline abstract_t">Bush NC, Xu L, Brown BJ, et al. Hospitalizations for pediatric stone disease in United States, 2002-2007. J Urol 2010; 183:1151.</a></li><li><a class="nounderline abstract_t">Dwyer ME, Krambeck AE, Bergstralh EJ, et al. Temporal trends in incidence of kidney stones among children: a 25-year population based study. J Urol 2012; 188:247.</a></li><li><a class="nounderline abstract_t">Walton RF, Yeh C, Shannon R, et al. Variation in care between pediatric and adult patients presenting with nephrolithiasis to tertiary care pediatric emergency departments in the United States (2009-2020). J Pediatr Urol 2022; 18:742.e1.</a></li><li><a class="nounderline abstract_t">Li Y, Bayne D, Wiener S, et al. Stone formation in patients less than 20 years of age is associated with higher rates of stone recurrence: Results from the Registry for Stones of the Kidney and Ureter (ReSKU). J Pediatr Urol 2020; 16:373.e1.</a></li><li><a class="nounderline abstract_t">Johnson CM, Wilson DM, O'Fallon WM, et al. Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int 1979; 16:624.</a></li><li><a class="nounderline abstract_t">Miyake O, Yoshimura K, Tsujihata M, et al. Possible causes for the low prevalence of pediatric urolithiasis. Urology 1999; 53:1229.</a></li><li><a class="nounderline abstract_t">Miyake O, Yoshimura K, Yoshioka T, et al. High urinary excretion level of citrate and magnesium in children: potential etiology for the reduced incidence of pediatric urolithiasis. Urol Res 1998; 26:209.</a></li><li><a class="nounderline abstract_t">Coward RJ, Peters CJ, Duffy PG, et al. Epidemiology of paediatric renal stone disease in the UK. Arch Dis Child 2003; 88:962.</a></li><li><a class="nounderline abstract_t">Gearhart JP, Herzberg GZ, Jeffs RD. Childhood urolithiasis: experiences and advances. Pediatrics 1991; 87:445.</a></li><li><a class="nounderline abstract_t">Diamond DA. Clinical patterns of paediatric urolithiasis. Br J Urol 1991; 68:195.</a></li><li><a class="nounderline abstract_t">Perrone HC, dos Santos DR, Santos MV, et al. Urolithiasis in childhood: metabolic evaluation. Pediatr Nephrol 1992; 6:54.</a></li><li><a class="nounderline abstract_t">Sarkissian A, Babloyan A, Arikyants N, et al. Pediatric urolithiasis in Armenia: a study of 198 patients observed from 1991 to 1999. Pediatr Nephrol 2001; 16:728.</a></li><li><a class="nounderline abstract_t">Issler N, Dufek S, Kleta R, et al. Epidemiology of paediatric renal stone disease: a 22-year single centre experience in the UK. BMC Nephrol 2017; 18:136.</a></li><li><a class="nounderline abstract_t">Huang WY, Chen YF, Chen SC, et al. Pediatric urolithiasis in Taiwan: a nationwide study, 1997-2006. Urology 2012; 79:1355.</a></li><li><a class="nounderline abstract_t">Novak TE, Lakshmanan Y, Trock BJ, et al. Sex prevalence of pediatric kidney stone disease in the United States: an epidemiologic investigation. Urology 2009; 74:104.</a></li><li><a class="nounderline abstract_t">Crivelli JJ, Maalouf NM, Paiste HJ, et al. Disparities in Kidney Stone Disease: A Scoping Review. J Urol 2021; 206:517.</a></li><li><a class="nounderline abstract_t">Milliner DS, Murphy ME. Urolithiasis in pediatric patients. Mayo Clin Proc 1993; 68:241.</a></li><li><a class="nounderline abstract_t">Stapleton FB. Nephrolithiasis in children. Pediatr Rev 1989; 11:21.</a></li><li><a class="nounderline abstract_t">Penido MG, Srivastava T, Alon US. Pediatric primary urolithiasis: 12-year experience at a Midwestern Children's Hospital. J Urol 2013; 189:1493.</a></li><li><a class="nounderline abstract_t">Spivacow FR, Del Valle EE, Boailchuk JA, et al. Metabolic risk factors in children with kidney stone disease: an update. Pediatr Nephrol 2020; 35:2107.</a></li><li><a class="nounderline abstract_t">Stapleton FB, McKay CP, Noe HN. Urolithiasis in children: the role of hypercalciuria. Pediatr Ann 1987; 16:980.</a></li><li><a class="nounderline abstract_t">Sas DJ, Becton LJ, Tutman J, et al. Clinical, demographic, and laboratory characteristics of children with nephrolithiasis. Urolithiasis 2016; 44:241.</a></li><li><a class="nounderline abstract_t">DeFoor W, Minevich E, Jackson E, et al. Urinary metabolic evaluations in solitary and recurrent stone forming children. J Urol 2008; 179:2369.</a></li><li><a class="nounderline abstract_t">Bergsland KJ, Coe FL, White MD, et al. Urine risk factors in children with calcium kidney stones and their siblings. Kidney Int 2012; 81:1140.</a></li><li><a class="nounderline abstract_t">Stapleton FB. Idiopathic hypercalciuria: association with isolated hematuria and risk for urolithiasis in children. The Southwest Pediatric Nephrology Study Group. Kidney Int 1990; 37:807.</a></li><li><a class="nounderline abstract_t">Stapleton FB. Hematuria associated with hypercalciuria and hyperuricosuria: a practical approach. Pediatr Nephrol 1994; 8:756.</a></li><li><a class="nounderline abstract_t">Garcia CD, Miller LA, Stapleton FB. Natural history of hematuria associated with hypercalciuria in children. Am J Dis Child 1991; 145:1204.</a></li><li><a class="nounderline abstract_t">De Santo NG, Di Iorio B, Capasso G, et al. Population based data on urinary excretion of calcium, magnesium, oxalate, phosphate and uric acid in children from Cimitile (southern Italy). Pediatr Nephrol 1992; 6:149.</a></li><li><a class="nounderline abstract_t">Kruse K, Kracht U, Kruse U. Reference values for urinary calcium excretion and screening for hypercalciuria in children and adolescents. Eur J Pediatr 1984; 143:25.</a></li><li><a class="nounderline abstract_t">Aladjem M, Barr J, Lahat E, Bistritzer T. Renal and absorptive hypercalciuria: a metabolic disturbance with varying and interchanging modes of expression. Pediatrics 1996; 97:216.</a></li><li><a class="nounderline abstract_t">Coe FL, Bushinsky DA. Pathophysiology of hypercalciuria. Am J Physiol 1984; 247:F1.</a></li><li><a class="nounderline abstract_t">Pak CY. Physiological basis for absorptive and renal hypercalciurias. Am J Physiol 1979; 237:F415.</a></li><li><a class="nounderline abstract_t">Weisinger JR. New insights into the pathogenesis of idiopathic hypercalciuria: the role of bone. Kidney Int 1996; 49:1507.</a></li><li><a class="nounderline abstract_t">Srivastava T, Alon US. Pathophysiology of hypercalciuria in children. Pediatr Nephrol 2007; 22:1659.</a></li><li><a class="nounderline abstract_t">Moe OW, Bonny O. Genetic hypercalciuria. J Am Soc Nephrol 2005; 16:729.</a></li><li><a class="nounderline abstract_t">Gambaro G, Vezzoli G, Casari G, et al. Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms. Am J Kidney Dis 2004; 44:963.</a></li><li><a class="nounderline abstract_t">Kollars J, Zarroug AE, van Heerden J, et al. Primary hyperparathyroidism in pediatric patients. Pediatrics 2005; 115:974.</a></li><li><a class="nounderline abstract_t">Bergstrom WH. Hypercalciuria and hypercalcemia complicating immobilization. Am J Dis Child 1978; 132:553.</a></li><li><a class="nounderline abstract_t">Hueppelshaeuser R, von Unruh GE, Habbig S, et al. Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn's disease. Pediatr Nephrol 2012; 27:1103.</a></li><li><a class="nounderline abstract_t">Bevill M, Kattula A, Cooper CS, Storm DW. The Modern Metabolic Stone Evaluation in Children. Urology 2017; 101:15.</a></li><li><a class="nounderline abstract_t">Kovacevic L, Wolfe-Christensen C, Edwards L, et al. From hypercalciuria to hypocitraturia--a shifting trend in pediatric urolithiasis? J Urol 2012; 188:1623.</a></li><li><a class="nounderline abstract_t">Tekin A, Tekgul S, Atsu N, et al. A study of the etiology of idiopathic calcium urolithiasis in children: hypocitruria is the most important risk factor. J Urol 2000; 164:162.</a></li><li><a class="nounderline abstract_t">Schärer K, Manz F. Renal handling of citrate in children with various kidney disorders. Int J Pediatr Nephrol 1985; 6:79.</a></li><li><a class="nounderline abstract_t">Welch BJ, Graybeal D, Moe OW, et al. Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis 2006; 48:555.</a></li><li class="breakAll">World Health Organization. Melamine and cyanuric acid: Toxicity, preliminary risk assessment and guidance on levels in food. September 25, 2008. Available at: www.who.int/foodsafety/fs_management/Melamine.pdf (Accessed on January 27, 2009).</li><li><a class="nounderline abstract_t">Parry J. China's tainted milk scandal spreads around world. BMJ 2008; 337:a1890.</a></li><li><a class="nounderline abstract_t">Guan N, Fan Q, Ding J, et al. Melamine-contaminated powdered formula and urolithiasis in young children. N Engl J Med 2009; 360:1067.</a></li><li><a class="nounderline abstract_t">Zhu SL, Li JH, Chen L, et al. Conservative management of pediatric nephrolithiasis caused by melamine-contaminated milk powder. Pediatrics 2009; 123:e1099.</a></li><li><a class="nounderline abstract_t">Lam HS, Ng PC, Chu WC, et al. Renal screening in children after exposure to low dose melamine in Hong Kong: cross sectional study. BMJ 2008; 337:a2991.</a></li><li><a class="nounderline abstract_t">Kielb S, Koo HP, Bloom DA, Faerber GJ. Nephrolithiasis associated with the ketogenic diet. J Urol 2000; 164:464.</a></li><li><a class="nounderline abstract_t">Herzberg GZ, Fivush BA, Kinsman SL, Gearhart JP. Urolithiasis associated with the ketogenic diet. J Pediatr 1990; 117:743.</a></li><li><a class="nounderline abstract_t">Furth SL, Casey JC, Pyzik PL, et al. Risk factors for urolithiasis in children on the ketogenic diet. Pediatr Nephrol 2000; 15:125.</a></li><li><a class="nounderline abstract_t">Sharma S, Gulati S, Kalra V, et al. Seizure control and biochemical profile on the ketogenic diet in young children with refractory epilepsy--Indian experience. Seizure 2009; 18:446.</a></li><li><a class="nounderline abstract_t">Hoppe B, Hesse A, Brömme S, et al. Urinary excretion substances in patients with cystic fibrosis: risk of urolithiasis? Pediatr Nephrol 1998; 12:275.</a></li><li><a class="nounderline abstract_t">Böhles H, Gebhardt B, Beeg T, et al. Antibiotic treatment-induced tubular dysfunction as a risk factor for renal stone formation in cystic fibrosis. J Pediatr 2002; 140:103.</a></li><li><a class="nounderline abstract_t">Tasian GE, Jemielita T, Goldfarb DS, et al. Oral Antibiotic Exposure and Kidney Stone Disease. J Am Soc Nephrol 2018; 29:1731.</a></li><li><a class="nounderline abstract_t">Edvardsson V, Palsson R, Olafsson I, et al. Clinical features and genotype of adenine phosphoribosyltransferase deficiency in iceland. Am J Kidney Dis 2001; 38:473.</a></li><li><a class="nounderline abstract_t">Runolfsdottir HL, Palsson R, Agustsdottir IM, et al. Long-term renal outcomes of APRT deficiency presenting in childhood. Pediatr Nephrol 2019; 34:435.</a></li><li><a class="nounderline abstract_t">Carpenter TO, Lebowitz RL, Nelson D, Bauer S. Hereditary xanthinuria presenting in infancy with nephrolithiasis. J Pediatr 1986; 109:307.</a></li><li class="breakAll">Sadler L, Stapleton FB. Disorders of porphyrin, purine, and phyridimine metabolism. In: Current Pediatric Therapy, 15th ed, Burg FD, Ingelfinger JR, Wald ER (Eds), WB Saunders, Philadelphia 1994.</li><li><a class="nounderline abstract_t">Zibolen M, Srsnova K, Srsen S. Increased urolithiasis in patients with alkaptonuria in childhood. Clin Genet 2000; 58:79.</a></li><li><a class="nounderline abstract_t">Samuel M, Duffy P, Capps S, et al. Xanthogranulomatous pyelonephritis in childhood. J Pediatr Surg 2001; 36:598.</a></li><li><a class="nounderline abstract_t">Bingöl-Koloğlu M, Ciftçi AO, Senocak ME, et al. Xanthogranulomatous pyelonephritis in children: diagnostic and therapeutic aspects. Eur J Pediatr Surg 2002; 12:42.</a></li><li><a class="nounderline abstract_t">Zugor V, Schott GE, Labanaris AP. Xanthogranulomatous pyelonephritis in childhood: a critical analysis of 10 cases and of the literature. Urology 2007; 70:157.</a></li><li><a class="nounderline abstract_t">Hussein N, Osman Y, Sarhan O, et al. Xanthogranulomatous pyelonephritis in pediatric patients: effect of surgical approach. Urology 2009; 73:1247.</a></li><li><a class="nounderline abstract_t">VanDervoort K, Wiesen J, Frank R, et al. Urolithiasis in pediatric patients: a single center study of incidence, clinical presentation and outcome. J Urol 2007; 177:2300.</a></li><li><a class="nounderline abstract_t">Sternberg K, Greenfield SP, Williot P, Wan J. Pediatric stone disease: an evolving experience. J Urol 2005; 174:1711.</a></li><li><a class="nounderline abstract_t">Fontaine E, Gagnadoux MF, Niaudet P, et al. Renal transplantation in children with augmentation cystoplasty: long-term results. J Urol 1998; 159:2110.</a></li></ol></div><div id="topicVersionRevision">Topic 6112 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31005657" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pediatric Urinary Stone Disease in the United States: The Urologic Diseases in America Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26769765" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Annual Incidence of Nephrolithiasis among Children and Adults in South Carolina from 1997 to 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29061537" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Increasing Prevalence of Nephrolithiasis in Association with Increased Body Mass Index in Children: A Population Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20650479" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiological trends in pediatric urolithiasis at United States freestanding pediatric hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20096871" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hospitalizations for pediatric stone disease in United States, 2002-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22595060" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Temporal trends in incidence of kidney stones among children: a 25-year population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35945144" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Variation in care between pediatric and adult patients presenting with nephrolithiasis to tertiary care pediatric emergency departments in the United States (2009-2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32280060" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Stone formation in patients less than 20 years of age is associated with higher rates of stone recurrence: Results from the Registry for Stones of the Kidney and Ureter (ReSKU).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/548606" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Renal stone epidemiology: a 25-year study in Rochester, Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10367860" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Possible causes for the low prevalence of pediatric urolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9694604" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : High urinary excretion level of citrate and magnesium in children: potential etiology for the reduced incidence of pediatric urolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14612355" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Epidemiology of paediatric renal stone disease in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2011420" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Childhood urolithiasis: experiences and advances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1884149" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical patterns of paediatric urolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1536741" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Urolithiasis in childhood: metabolic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11511987" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pediatric urolithiasis in Armenia: a study of 198 patients observed from 1991 to 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28420322" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Epidemiology of paediatric renal stone disease: a 22-year single centre experience in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22465087" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pediatric urolithiasis in Taiwan: a nationwide study, 1997-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19428065" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sex prevalence of pediatric kidney stone disease in the United States: an epidemiologic investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33904797" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Disparities in Kidney Stone Disease: A Scoping Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8474265" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Urolithiasis in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2664747" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nephrolithiasis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23201378" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pediatric primary urolithiasis: 12-year experience at a Midwestern Children's Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32564280" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Metabolic risk factors in children with kidney stone disease: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3320916" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Urolithiasis in children: the role of hypercalciuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26467033" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical, demographic, and laboratory characteristics of children with nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18433777" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Urinary metabolic evaluations in solitary and recurrent stone forming children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22358148" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Urine risk factors in children with calcium kidney stones and their siblings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2407891" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Idiopathic hypercalciuria: association with isolated hematuria and risk for urolithiasis in children. The Southwest Pediatric Nephrology Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7696121" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hematuria associated with hypercalciuria and hyperuricosuria: a practical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1928018" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Natural history of hematuria associated with hypercalciuria in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1571211" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Population based data on urinary excretion of calcium, magnesium, oxalate, phosphate and uric acid in children from Cimitile (southern Italy).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6510426" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Reference values for urinary calcium excretion and screening for hypercalciuria in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8584380" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Renal and absorptive hypercalciuria: a metabolic disturbance with varying and interchanging modes of expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6377922" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pathophysiology of hypercalciuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/229736" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Physiological basis for absorptive and renal hypercalciurias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8731119" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : New insights into the pathogenesis of idiopathic hypercalciuria: the role of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17464515" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pathophysiology of hypercalciuria in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15689405" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Genetic hypercalciuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15558518" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15805373" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Primary hyperparathyroidism in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/350037" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hypercalciuria and hypercalcemia complicating immobilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22366809" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27838366" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The Modern Metabolic Stone Evaluation in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22910255" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : From hypercalciuria to hypocitraturia--a shifting trend in pediatric urolithiasis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10840454" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A study of the etiology of idiopathic calcium urolithiasis in children: hypocitruria is the most important risk factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3997374" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Renal handling of citrate in children with various kidney disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16997051" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Biochemical and stone-risk profiles with topiramate treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16997051" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Biochemical and stone-risk profiles with topiramate treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18829644" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : China's tainted milk scandal spreads around world.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19196669" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Melamine-contaminated powdered formula and urolithiasis in young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19482743" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Conservative management of pediatric nephrolithiasis caused by melamine-contaminated milk powder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19097976" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Renal screening in children after exposure to low dose melamine in Hong Kong: cross sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893623" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Nephrolithiasis associated with the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2231206" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Urolithiasis associated with the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095028" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Risk factors for urolithiasis in children on the ketogenic diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19427240" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Seizure control and biochemical profile on the ketogenic diet in young children with refractory epilepsy--Indian experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9655356" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Urinary excretion substances in patients with cystic fibrosis: risk of urolithiasis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11815772" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Antibiotic treatment-induced tubular dysfunction as a risk factor for renal stone formation in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29748329" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Oral Antibiotic Exposure and Kidney Stone Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11532677" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Clinical features and genotype of adenine phosphoribosyltransferase deficiency in iceland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30443743" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Long-term renal outcomes of APRT deficiency presenting in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3755469" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Hereditary xanthinuria presenting in infancy with nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3755469" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hereditary xanthinuria presenting in infancy with nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10945668" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Increased urolithiasis in patients with alkaptonuria in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11283885" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Xanthogranulomatous pyelonephritis in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11967759" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Xanthogranulomatous pyelonephritis in children: diagnostic and therapeutic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17656228" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Xanthogranulomatous pyelonephritis in childhood: a critical analysis of 10 cases and of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19362329" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Xanthogranulomatous pyelonephritis in pediatric patients: effect of surgical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17509344" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Urolithiasis in pediatric patients: a single center study of incidence, clinical presentation and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16148688" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pediatric stone disease: an evolving experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9598551" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Renal transplantation in children with augmentation cystoplasty: long-term results.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
